百利天恒：iza-bren(EGFR×HER3双抗ADC)用于局部晚期或转移性三阴乳腺癌III期临试期中分析达到主要终点

Core Viewpoint - Bailitianheng (688506.SH) announced that its drug iza-bren (EGFR×HER3 bispecific antibody ADC) has achieved the primary endpoint in a Phase III clinical trial for locally advanced or metastatic triple-negative breast cancer [1] Group 1: Clinical Trial Results - The independent data monitoring committee (iDMC) recommended early communication with regulators based on the interim analysis results while continuing to follow up with participants [1] - Topline data indicates that iza-bren significantly extended progression-free survival (PFS) and overall survival (OS), achieving dual primary endpoints [1] - This Phase III clinical trial is the third to reach primary endpoints for the bispecific antibody ADC and is the first globally to achieve positive PFS/OS results in triple-negative breast cancer treatment [1]